학술논문
Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial.
Document Type
clinical trial
Author
Source
Annals of the Rheumatic Diseases; Oct2019, Vol. 78 Issue 10, p1439-1441, 3p, 1 Chart, 1 Graph
Subject
Language
ISSN
00034967